Poseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report) – Investment analysts at HC Wainwright upped their Q2 2024 EPS estimates for Poseida Therapeutics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst A. He now anticipates that the company will earn ($0.43) per share for the quarter, up from […]
HC Wainwright Reaffirms Buy Rating for Poseida Therapeutics (NASDAQ:PSTX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Poseida Therapeutics (NASDAQ:PSTX) Given "Buy" Rating at HC Wainwright themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its target price upped by HC Wainwright from $15.00 to $20.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald […]
Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its price objective increased by HC Wainwright from $15.00 to $20.00 in a research note released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald restated an […]